Aliri launches next-gen CyTOF assay for single-cell profiling
Aliri Bioanalysis has launched the CyTOF Inflammatory Response Assay, streamlining single cell analysis into one powerful method.
Aliri Bioanalysis (CO, USA) has announced the launch of its next-generation Cytometry by Time-Of-Flight (CyTOF) Inflammatory Response Assay, a transformative technique for high-resolution, single-cell profiling and cytokine analysis. Blending mass spectrometry and flow cytometry techniques, the assay offers a more efficient, cost-effective alternative to traditional flow cytometry and ligand binding assays.
Real-time insights into a drug’s mechanism of action, safety, efficacy and immunomodulatory effects are essential for precision bioanalysis. As the demand for personalized treatments continues to rise, the need for innovative bioanalytical solutions has never been greater. One such breakthrough is CyTOF, which could transform the landscape of high-dimensional single-cell analysis.
You may also be interested in:
- The current status of single-cell proteomics for biomedical research
- In the Zone: the importance of monitoring assay performance and maintenance
- Panel discussion: evolving best practices in high-complexity flow cytometry
CyTOF supports a wide range of applications, including immunophenotyping, cancer immunotherapy, immune cell profiling, single-cell functional analysis and infectious disease research. Enabling researchers to analyze over 40 markers per cell in a single run—without the complications of autofluorescence, spectral overlap or the need for PBMC processing and cold-chain logistics—the assay delivers highly multiplexed data with minimal background noise.
“Our skilled team of scientists have over 5 years of experience using this multi-omics single-cell method on various matrices to support cellular immunophenotyping and inflammatory response monitoring, as it provides sponsors with a more detailed understanding of complex immune cell populations including their function and activation,” explained Corinne Ramos, Aliri’s R&D Director.
CyTOF can deliver 46-marker analysis directly tied to specific cell types from a single blood draw, eliminating the need for costly and time-consuming separate flow cytometry and ligand binding assays. It offers deeper immune insights, reduced sample volumes, and can be customized and validated for specific markers within varied therapeutic areas.
With the launch of the CyTOF assay, Aliri has reinforced its position as a leader in precision bioanalysis, enabling deeper insights into immunotherapies, vaccine responses and inflammation, while supporting drug development through advanced and customizable bioanalytical solutions.
